# EDGAR Filing Document

**Accession Number:** 0001828673
**File Stem:** 0001193125-25-181394
**Filing Date:** 2025-8
**Character Count:** 8440
**Document Hash:** ed94abb961c84eb8983d627a91b16ea7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-181394.hdr.sgml**: 20250815

**ACCESSION NUMBER**: 0001193125-25-181394

**CONFORMED SUBMISSION TYPE**: NT 10-Q

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250815

**DATE AS OF CHANGE**: 20250815

**EFFECTIVENESS DATE**: 20250815

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HCW Biologics Inc.
- **CENTRAL INDEX KEY:** 0001828673
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825024477
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NT 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40591
- **FILM NUMBER:** 251222761

**BUSINESS ADDRESS:**
- **STREET 1:** 2929 N COMMERCE PKWY
- **CITY:** MIRAMAR
- **STATE:** FL
- **ZIP:** 33025
- **BUSINESS PHONE:** 954-842-2024

**MAIL ADDRESS:**
- **STREET 1:** 2929 N COMMERCE PKWY
- **CITY:** MIRAMAR
- **STATE:** FL
- **ZIP:** 33025

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 12b-25** 

**NOTIFICATION OF LATE FILING** 

---

| | |
|:---|:---|
| *(Check One):* | ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q<br> ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR |
|  | For Period Ended: June 30, 2025 |
|  | ☐ Transition Report on Form 10-K |
|  | ☐ Transition Report on Form 20-F |
|  | ☐ Transition Report on Form 11-K |
|  | ☐ Transition Report on Form 10-K |
|  | For the Transition Period Ended:<u> </u> |

---

&nbsp;&nbsp;&nbsp; *Read Instructions (on back page) Before Preparing Form. Please Print or Type.*<br> **NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.**<br>

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**PART I — REGISTRANT INFORMATION** 

---

| | |
|:---|:---|
| **Full Name of Registrant:** | **HCW Biologics Inc.** |
| **Former Name if Applicable:** | **NA** |
| **Address of Principal Executive Office *(Street and Number):*** | **2929 North Commerce Parkway** |
| **City, State and Zip Code:** | **Miramar, FL 33025** |

---

**PART II — RULES 12b-25(b) AND (c)** 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;☒ | (a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;<br>|
| &nbsp;&nbsp;&nbsp;☒ | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and<br>|
| &nbsp;&nbsp;&nbsp;☒ | (c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

---

**PART III — NARRATIVE** 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant is unable to file its Form 10-Q for the quarter ended June 30, 2025 within the prescribed time period without unreasonable effort or expense because the Registrant needed additional time to prepare its financial statements for the three months ended June 30, 2025. The Registrant anticipates that it will file its Form 10-Q within the five-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

**PART IV — OTHER INFORMATION** 

---

| | | | |
|:---|:---|:---|:---|
| (1) | Name and telephone number of person to contact in regard to this notification: | Name and telephone number of person to contact in regard to this notification: | Name and telephone number of person to contact in regard to this notification: |
|  | **Rebecca Byam** | **954** | **842-2024 X252** |
|  | **(Name)** | **(Area Code)** | **(Telephone Number)** |
| (2) | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No | Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No |
| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No |
| If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. In Q2 2024, HCW Biologics Inc. was involved in preparation and hearings for a long-running arbitration, which was settled shortly after Q2 2024 on July 13, 2024. Legal fees incurred by HCW Biologics Inc. in Q2 2024 were $10.4 million versus $142,452 in the same period in 2025. | If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. In Q2 2024, HCW Biologics Inc. was involved in preparation and hearings for a long-running arbitration, which was settled shortly after Q2 2024 on July 13, 2024. Legal fees incurred by HCW Biologics Inc. in Q2 2024 were $10.4 million versus $142,452 in the same period in 2025. | If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. In Q2 2024, HCW Biologics Inc. was involved in preparation and hearings for a long-running arbitration, which was settled shortly after Q2 2024 on July 13, 2024. Legal fees incurred by HCW Biologics Inc. in Q2 2024 were $10.4 million versus $142,452 in the same period in 2025. | If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. In Q2 2024, HCW Biologics Inc. was involved in preparation and hearings for a long-running arbitration, which was settled shortly after Q2 2024 on July 13, 2024. Legal fees incurred by HCW Biologics Inc. in Q2 2024 were $10.4 million versus $142,452 in the same period in 2025. |

---

**HCW Biologics Inc.** 

**(Name of Registrant as Specified in Charter)** 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | August 15, 2025 | By: | */s/ Rebecca Byam* |
|  |  |  | Rebecca Byam |
|  |  |  | Chief Financial Officer |

---